SYNERCID POWDER FOR SOLUTION Kanada - angielski - Health Canada

synercid powder for solution

monarch pharmaceuticals ireland limited - quinupristin; dalfopristin - powder for solution - 150mg; 350mg - quinupristin 150mg; dalfopristin 350mg - streptogramins

CONDYLOX podofilox solution Stany Zjednoczone - angielski - NLM (National Library of Medicine)

condylox podofilox solution

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml

CONDYLOX podofilox gel Stany Zjednoczone - angielski - NLM (National Library of Medicine)

condylox podofilox gel

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g

CONDYLOX- podofilox gel Stany Zjednoczone - angielski - NLM (National Library of Medicine)

condylox- podofilox gel

allergan, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g - condylox gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). this product is not indicated in the treatment of mucous membrane warts (see precautions ). although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma and "bowenoid papulosis" is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 0.5%. condylox gel 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any components of the formulation.